Interleukin 12

Patients with psoriasis treated with interleukin-12/23 or IL-23 inhibitors may be less likely to progress to inflammatory arthritis than those treated with TNF inhibitors, according to data published in The Lancet Rheumatology.

Ustekinumab failed to demonstrate superiority to placebo among patients with active systemic lupus erythematosus, according to phase-3 data published in Annals of the Rheumatic Diseases.

Although a range of biologic options are available to clinicians treating psoriatic arthritis, it crucial to know which disease domains are involved as this will “dictate treatment,” according to a presenter at the Biologic Therapies Summit.